INSIGHTS ON CELL & GENE MANUFACTURING AND LOGISTICS
-
Universalizing Allogeneic Cell Therapies With Cord-Blood-Derived Stem Cells
Coeptis Therapeutics' new CSO, Dr. Colleen Delaney, explains why she thinks umbilical cord blood is the best source of starting material for allogeneic cell therapies.
-
Advances In CRISPR Disease Modeling
Disease modeling helps us understand disease and create therapies. Learn about the types of disease models, the impact of CRISPR, current challenges, and trends.
-
Overcoming Challenges In AAV And LV Viral Vector Manufacturing
Learn more about the platform-based scalable suspension process for LVV production and how it is impacting CGTs advancing toward commercialization.
-
HEK293T Cell Expansion Protocol Using A Hollow-Fiber Bioreactor System
Explore the use of a hollow-fiber bioreactor (HFB) system for the automated expansion of HEK293T cells and a protocol used to help users of the system.
-
How To Lose A Batch In 10 Days
Inspired by the rom com How to Lose a Guy in 10 Days, this article spotlights the critical missteps that could lead you to lose a batch during the manufacturing process. By identifying these pitfalls, the author guides you toward best practices that will not only save your batches but also improve the quality, efficiency, and reliability of your operations.
-
Advancing Policy To Improve Safety And Efficacy For Cell And Gene Therapies
Achieving greater specificity for cell and gene therapy regulatory guidance is crucial, but even more crucial is establishing guidance informed by patient experience.
-
Scaling Up Your Methods With USP <621> - Part 2: Hardware
Learn about the hardware changes that allow for scaling and modernization of chromatographic methods and how mismatching particle size and liquid chromatographic systems can result in poor performance.
-
Scaling Up Your Methods With USP <621> - Part 1: Chemistry
Explore the latest updates to the USP <621> guidelines that involve changes to the allowable modifications to gradient methods and updates to system suitability parameters.
-
Scaling Up Your Methods with USP <621> - Part 3: Software
Learn how Empower Software addresses modifications to certain calculations and maintains relevant naming conventions and calculations to help customers update SOPs to prevent disruption to operations.
-
Monitoring And Determining The Cause Of Antibody Discoloration Using cIEF And EAD
View a study which provides additional insight into the factors that govern the discoloration of protein therapeutics and the role of AGEs in color change.